See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article for LPTN, TLOG, HTM, VSTN
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. – If you want reports on the day’s hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
Verastem, Inc. (NASDAQ: VSTM) Is a biopharmaceutical company that focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways.
TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) Is a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases.
TLOG has been moving higher since early April, with several big days intermingled with some low volume days, however, yesterday was a different story.
TLOG ran up 66% off 16 times its average volume yesterday. We are hoping to see that this kind of run continues in this new biotech as the stock is up over 100% in April.
U.S. Geothermal Inc. (NYSE: HTM) Is a renewable energy company, focuses on the development, production, and sale of electricity from geothermal energy in the Western United States.
We started following HTM back in early March. Since then, the stock has made steady, but impressive gains of about 1 to 4 percent on most days.
Yesterday Aegis Capital initiated coverage on HTM and the stock got an influx of volume. The stock only made gains of 4% off the coverage announcement, however, this is a good sign that this slow and steady stock is going to continue making gains in the near future.
Lpath Inc. (NASDAQ: LPTN) Is a biotechnology company that focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States.
Shares of LPTN traded higher yesterday by over 24%. The stock appears to be continuing its trend higher in early 2016. However, since April, the stock has really been taking off, seeing an increase in volume and price increase, especially after breaking out past its 50 and 200 day MA (moving averages).
On April 19th the company announced the completion of its Phase 1 double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab™ in healthy volunteers.
Source- The OTC Expert
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.
